Curidium Medica PLC-Strategic Review & Board Changes


LONDON--(Marketwire - July 23, 2008) -


Press Release 23 July 2008

Curidium Medica Plc

("Curidium" or "the Company")

Strategic Review and Board Changes


London, UK, 23 July 2008, Curidium Medica plc, (LSE: CUR), the
personalised medicine company focused on bringing the right drug to the
right patient, today announced that Gosse B. Bruinsma M.D. is moving
from chairman to the position of Non-Executive Director. Dr. Barry
Porter, co-founder and currently Non-Executive Director,
becomes Chairman, with immediate effect. Dr. Bruinsma has cited his
other business obligations and Curidium's need for dedicated leadership
at this important time as reasons for the strategic change.


Led by Dr Porter, Curidium has initiated a strategic review to maximise
its commercial development opportunities. With the pharmaceutical
industry's growing interest in personalised medicine the Company will
ensure its intellectual property assets and strong balance
sheet are fully utilised to deliver optimum value to shareholders.


Curidium will enhance its R&D activities, with
the aim of fully leveraging its product portfolio in support of
business development activities as the Company continues to receive
positive feedback from customers on PsychINDxTM: a diagnostic blood test
that classifies patients with schizophrenia/bipolar disorder into
different subgroups, which may result in the improved treatment of
these patients.

Commenting on the reorganisation, Dr. Porter, Chairman, said: "On
behalf of the Board, I would like to thank Gosse for his contribution
and achievements during his time as Chairman.  This is a very exciting
time for Curidium; the regulators and leading drug companies are
beginning to recognise the significant importance of personalised
medicines and I believe the Company is well placed to capitalise on
this in the near future."

ends

For further information:

Curidium Medica plc

Barry Porter, Chairman      +44 (0) 20 7554 5100


Rob Smith, Finance Director +44 (0) 20 7554 5102

                            http://www.curidium.com/

FinnCap

Charles Cunningham          +44 (0) 20 7600 1658

                            http://www.jmfinncapitalmarkets.com/


Media enquiries:

Abchurch                                 Tel: +44 (0) 20 7398 7700

Heather Salmond / Stephanie Cuthbert /   Tel: +44 (0) 20 7398 7718
Simone Alves

                                         Tel: +44 (0) 20 7398 7728

stephanie.cuthbert@abchurch-group.com    www.abchurch-group.com


Notes to Editors

About Dr Barry Porter, Chairman, Curidium Medica Plc

Barry is a Director of Union Life Sciences and a Non-Executive Director
of Inhibox Limited. Barry has almost thirty years of drug discovery
experience working in the pharmaceutical industry. He was Chief
Executive of ReOx Ltd, a biotechnology spin out from
the University of Oxford which entered into a ground breaking
co-development deal with a major international biopharmaceutical
company in its first year of operations. Prior to these roles, Barry
held senior positions at De Novo Pharmaceuticals, Pharmagene, now
Asterand, Rhone-Poulenc Rorer and Glaxo Group Research. He gained his
PhD from the University of California, San Diego followed by a post
doctoral fellowship with Syntex in Palo Alto.


About Curidium Medica

Curidium is a personalised medicine company identifying targeted
medicines and companion diagnostics to treat patients more effectively.


Curidium's initial focus on diseases of the Central Nervous System has
resulted in the identification of a blood diagnostic test, PsychINDxTM,
which classifies patients with schizophrenia/bipolar disorder into four
subgroups. PsychINDxTM may have the potential to improve the treatment
of patients with schizophrenia/bipolar disorder, by targeting the right
drug to the right patient subgroup.

Many chronic human diseases are heterogeneous and their patient
populations consist of mixed subgroups. Through the use of its
proprietary analysis tool, Homomatrix®, Curidium aims to reveal
different patient subgroups characterised by distinct underlying
disease mechanisms potentially leading to the identification of:

1. Diagnostics for better identification and treatment within
   heterogeneous disease populations.
2. Improved therapies identified through novel drug targets.
3. Personalised medicines using companion diagnostics and targeted
   treatments.

Curidium aims to continue to use this approach to improve patient
treatments in a variety of therapeutic areas.
Curidium Medica plc © 2002-2008. All rights reserved.
Studio 10, Tiger House, Burton Street, London WC1H 9BY, United Kingdom.
Email: info@curidium.com Tel.: +44 (0)20 7554 5100, Fax: +44 (0)20 7383
2973


                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com